Accelmed Partners completed a $35m investment in SKNV.

Accelmed Partners, a US-based private equity firm, completed a $35m investment in SKNV, a pioneer in customized medications and skincare solutions for dermatology practices across the United States. "We are partnering with Accelmed because they share in our vision for a dermatology ecosystem that connects local practices and customized medicine with the latest in digital health technologies to drive patient care compliance and prescription drug adherence. The real future of healthcare combines digital and local care to improve patient outcomes. As others continue their pursuits to displace dermatology practices, SKNV empowers community doctors with the advanced, customized solutions that modern patients seek without losing the personal care from local providers they trust. Accelmed’s operational expertise and industry-wide connections are key to expediting our growth from an innovative market leader in customized medicine to the new pharma standard for dermatology," Spencer Malkin, SKNV Founder and CEO.